drugset / Trial / NCT03699384

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

NCT03699384 ↗

NaSingle-groupOpen-labelTreatment

Summary

This is a phase I / II study. The purposes of this study are to: 1) find out what effects, good and/or bad, the combination of the experimental drug avelumab and the drug azacitidine has on people with AML and MRD, and 2) test if the two drugs, avelumab and azacitidine, are effective in getting rid of AML MRD when the drugs are given together in combination.

Timeline

Start
2018-10-03
Primary completion
2019-02-18
Completion
2019-02-18

Outcome

Outcome not reported

Stopped: “Study sponsor discontinued support”

Drugs

EvaluationDrugModalityDoseRoute
Subject Avelumab Monoclonal antibody 10 mg/kg Intravenous
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous